Cover Image
Market Research Report

Global Non-invasive Prenatal Testing Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 369186
Published Content info 86 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Non-invasive Prenatal Testing Market 2017-2021
Published: November 2, 2017 Content info: 86 Pages
Description

About Non-invasive Prenatal Testing

Non-invasive prenatal screening is performed primarily by ultrasonography and serum testing from maternal plasma. Ultrasonography uses the clear tissue behind the infant's neck to detect genetic defects. A fetus with abnormalities tends to accumulate more fluid. Hence, more clear space is detected behind the neck, which is an indicative measure. Maternal serum screening is a method that involves blood testing in the first and second trimester of the gestation period where specific chemicals such as pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (HCG) are checked.

Technavio's analysts forecast the global non-invasive prenatal testing market to grow at a CAGR of 16.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global non-invasive prenatal testing market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Non-invasive Prenatal Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • BGI Genomics
  • Illumina
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics

Other Prominent Vendors

  • Agilent Technologies
  • Berry Genomics
  • F. Hoffman-La Roche
  • LifeCodexx
  • Natera
  • PerkinElmer

Market driver

  • Advantages of non-invasive methods over invasive methods
  • For a full, detailed list, view our report

Market challenge

  • Abortion rate and ethical hurdles
  • For a full, detailed list, view our report

Market trend

  • Increase in acceptance of NIPT
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR15498

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Overview

PART 05: MARKET LANDSCAPE

  • Overview
  • Market size and forecast
  • Five forces analysis

PART 06: SEGMENTATION BY APPLICATION

  • Overview
  • Trisomy
  • Microdeletions
  • Others

PART 07: SEGMENTATION BY END-USER

  • Overview
  • Diagnostic centers
  • Hospitals

PART 08: SEGMENTATION BY GEOGRAPHY

  • Overview
  • Regional comparison
  • NIPT market in Americas
  • NIPT market in EMEA
  • NIPT market in APAC
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increase in acceptance of NIPT
  • Increase in genetic counseling
  • Growth of genetic screening programs at births

PART 12: VENDOR LANDSCAPE

  • Competitive scenario
  • Investment opportunities

PART 13: KEY VENDOR ANALYSIS

  • BGI Genomics
  • Illumina
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics
  • Other prominent vendors

PART 14: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Types of prenatal diagnosis and screening
  • Exhibit 02: Lifecycle of prenatal testing techniques
  • Exhibit 03: Comparative analysis of NIPT with other techniques
  • Exhibit 04: Global NIPT market: Overview 2017-2021
  • Exhibit 05: Global NIPT market 2016-2021 ($ millions)
  • Exhibit 06: Five forces analysis
  • Exhibit 07: Global NIPT market: Segmentation by application 2016 (% share)
  • Exhibit 08: Global NIPT market: Segmentation by application 2021 (% share)
  • Exhibit 09: Global NIPT market: Segmentation by application 2016-2021 (% share)
  • Exhibit 10: Global NIPT by trisomy market 2016-2021 ($ millions)
  • Exhibit 11: Global NIPT by microdeletions market 2016-2021 ($ millions)
  • Exhibit 12: Global NIPT by others market 2016-2021 ($ millions)
  • Exhibit 13: Global NIPT market: Segmentation by end-user 2016-2021 (% share)
  • Exhibit 14: Global NIPT market by diagnostic centers 2016-2021 ($ millions)
  • Exhibit 15: Global NIPT market by hospitals 2016-2021 ($ millions)
  • Exhibit 16: Global NIPT market: Segmentation by geography 2016-2021 (% share)
  • Exhibit 17: Global NIPT market: Regional comparison
  • Exhibit 18: NIPT market in Americas 2016-2021($ millions)
  • Exhibit 19: NIPT market in Americas: Year-over-year growth 2017-2021 (%)
  • Exhibit 20: NIPT market in EMEA 2016-2021 ($ millions)
  • Exhibit 21: NIPT market in EMEA: Year-over-year growth (%) (2017-2021)
  • Exhibit 22: NIPT market in APAC 2016-2021 ($ million)
  • Exhibit 23: NIPT market in APAC: Year-over-year growth 2017-2021 (%)
  • Exhibit 24: Global NIPT market: Key leading countries
  • Exhibit 25: Global NIPT market: Growth and success factors of vendors
  • Exhibit 26: Global NIPT market: Investment opportunity mapping
  • Exhibit 27: BGI Genomics: Overview
  • Exhibit 28: BGI Genomics: Strength analysis
  • Exhibit 29: BGI Genomics: Strategy assessment
  • Exhibit 30: BGI Genomics opportunity assessment
  • Exhibit 31: Illumina: Overview
  • Exhibit 32: Illumina: Strength analysis
  • Exhibit 33: Illumina: Strategy assessment
  • Exhibit 34: Illumina: Opportunity assessment
  • Exhibit 35: Laboratory Corporation of America Holdings: Overview
  • Exhibit 36: Laboratory Corporation of America Holdings: Strength analysis
  • Exhibit 37: Laboratory Corporation of America Holdings: Strategy assessment
  • Exhibit 38: Laboratory Corporation of America Holdings: Opportunity assessment
  • Exhibit 39: Quest Diagnostics Overview
  • Exhibit 40: Quest Diagnostics: Strength analysis
  • Exhibit 41: Quest Diagnostics: Strategy assessment
  • Exhibit 42: Quest Diagnostics: Opportunity assessment
Back to Top